Publications

Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.

Neuzil, KM; Bresee, JS; De la Hoz, F; Johansen, K; Karron, RA; Krishnan, A; Madhi, SA; MANGTANI, P; Spiro, DJ; Ortiz, JR; WHO Preferred Product Characteristics for Next-Gen,;

2017

Vaccine, (2017).35 43 10.1016/j.vaccine.2017.08.088.

Facilitators and barriers of parental attitudes and beliefs toward school-located influenza vaccination in the United States: Systematic review.

Kang, GJ; Culp, RK; ABBAS, KM;

2017

Vaccine, (2017).35 16 10.1016/j.vaccine.2017.03.014.

Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.

GREENWOOD, B; Dicko, A; Sagara, I; Zongo, I; Tinto, H; CAIRNS, M; KUEPFER, I; MILLIGAN, P; Ouedraogo, J-B; Doumbo, O; CHANDRAMOHAN, D;

2017

Malaria journal, (2017).16 1 10.1186/s12936-017-1841-9.

Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.

Wichmann, O; Vannice, K; Asturias, EJ; De Albuquerque Luna, EJ; Longini, I; Lopez, AL; SMITH, PG; Tissera, H; Yoon, I-K; Hombach, J;

2017

Vaccine, (2017).35 42 10.1016/j.vaccine.2017.08.066.

A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Zak, DE; Penn-Nicholson, A; Scriba, TJ; Thompson, E; Suliman, S; Amon, LM; Mahomed, H; Erasmus, M; Whatney, W; Hussey, GD; Abrahams, D; Kafaar, F; Hawkridge, T; Verver, S; Hughes, EJ; Ota, M; SUTHERLAND, J; Howe, R; DOCKRELL, HM; Boom, WH; Thiel, B; Ottenhoff, TH M; Mayanja-Kizza, H; CRAMPIN, AC; Downing, K; ... ACS and GC6-74 cohort study groups,

2016

Lancet, (2016).387 10035 10.1016/S0140-6736(15)01316-1.

A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.

Sirima, SB; Mordmüller, B; MILLIGAN, P; Ngoa, UA; Kironde, F; Atuguba, F; Tiono, AB; Issifou, S; Kaddumukasa, M; Bangre, O; Flach, C; Christiansen, M; Bang, P; Chilengi, R; Jepsen, S; Kremsner, PG; Theisen, M; GMZ2 Trial Study Group,;

2016

Vaccine, (2016).34 38 10.1016/j.vaccine.2016.07.041.

Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya.

Nyiro, JU; Sande, CJ; Mutunga, M; Kiyuka, PK; Munywoki, PK; SCOTT, JA G; Nokes, DJ;

2016

PloS one, (2016).11 11 10.1371/journal.pone.0166706.

Cohort Profile: The Flu Watch Study.

FRAGASZY, EB; WARREN-GASH, C; Wang, L; Copas, A; Dukes, O; EDMUNDS, WJ; Goonetilleke, N; Harvey, G; Johnson, AM; Kovar, J; Lim, MS; McMichael, A; MILLETT, ER; Nazareth, I; Nguyen-Van-Tam, JS; Tabassum, F; Watson, JM; Wurie, F; Zambon, M; Hayward, AC; Flu Watch Group,;

2016

International journal of epidemiology, (2016).46 2 10.1093/ije/dyv370.

Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines.

HARRIS, RC; SUMNER, T; KNIGHT, GM; WHITE, RG;

2016

Human vaccines & immunotherapeutics, (2016).12 11 10.1080/21645515.2016.1205769.

Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection.

Sepúlveda, N; Morais, CG; Mourão, LC; Freire, MF; Fontes, CJ F; Lacerda, MV G; DRAKELEY, CJ; Braga, ÉM;

2016

Malaria journal, (2016).15 1 10.1186/s12936-016-1612-z.